Click here to visit Original posting
If these black marks on the industry are slowing down 31-year-old Vivek Ramaswamy in any way, you wouldn’t know it. He thinks his company, Roivant, will one day be a giant holding company for dozens of independent biopharmaceutical companies – both by developing drugs as well as focusing squarely on reducing the time and cost of the drug development process.
It all sounds rather lofty. Read More